Please use this identifier to cite or link to this item:
10.1016/j.phrs.2023.106771
| Title: | Sigma-1 receptor and seizures |
| Authors: | Vavers, Edijs Zvejniece, Liga Dambrova, Maija Faculty of Pharmacy |
| Keywords: | 3.1 Basic medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database |
| Issue Date: | May-2023 |
| Citation: | Vavers , E , Zvejniece , L & Dambrova , M 2023 , ' Sigma-1 receptor and seizures ' , Pharmacological Research , vol. 191 , 106771 . https://doi.org/10.1016/j.phrs.2023.106771 |
| Abstract: | Over the last decade, sigma-1 receptor (Sig1R) has been recognized as a valid target for the treatment of seizure disorders and seizure-related comorbidities. Clinical trials with Sig1R ligands are underway testing therapies for the treatment of drug-resistant seizures, developmental and epileptic encephalopathies, and photosensitive epilepsy. However, the direct molecular mechanism by which Sig1R modulates seizures and the balance between excitatory and inhibitory pathways has not been fully elucidated. This review article aims to summarize existing knowledge of Sig1R and its involvement in seizures by focusing on the evidence obtained from Sig1R knockout animals and the anti-seizure effects of Sig1R ligands. In addition, this review article includes a discussion of the advantages and disadvantages of the use of existing compounds and describes the challenges and future perspectives on the use of Sig1R as a target for the treatment of seizure disorders. |
| Description: | Funding Information: This review article was supported by the European Regional Development Fund Project No. 1.1.1.2/VIAA/2/18/376 "Sigma chaperone protein as a novel drug target". Authors were supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 857394 . EV would like to thank Jolanta Jonane for helping with the tables and references. Funding Information: This review article was supported by the European Regional Development Fund Project No. 1.1.1.2/VIAA/2/18/376 "Sigma chaperone protein as a novel drug target". Authors were supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 857394. EV would like to thank Jolanta Jonane for helping with the tables and references. Publisher Copyright: © 2023 The Authors |
| DOI: | 10.1016/j.phrs.2023.106771 |
| ISSN: | 1043-6618 |
| Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| Sigma_1_receptor_and_seizures.pdf | 2.15 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.